picked from Motif website19 Jun 2018 15:35
Iclaprim was well tolerated in the two Phase 3 studies compared to vancomycin. In most patients, adverse events were mild to moderate, with severe adverse events reported in less than 5% of all patients in the pooled data set. The most frequent adverse reactions in both iclaprim and vancomycin-treated patients were headache and nausea. No deaths occurred among patients treated with iclaprim, while three deaths occurred in the vancomycin group.
Acute kidney injury or elevated serum creatinine was reported in seven patients treated with vancomycin, which is known to be nephrotoxic. In contrast, none of the patients treated with iclaprim experienced acute kidney injury or elevated serum creatinine.
Clearly Iclaprim performed better than SoC(vancomycin). How many drugs recently have been successful and performed better than SoC? How many had 2 successful P3 trials?
Once FDA approves the drug, Motif is going to make millions and SP is going to be several times more than current price unless Pfizer makes an offer and steals it for a cheaper price!
Current MCap is just under 100M so any offer should be atleast 500M ? SP then would be £1.68 ?